key: cord-0960335-pbeo2ffn
authors: Lemoine, Chantal; Giacobbe, Alaina G.; Bonifacino, Eliana; Karapetyan, Lilit; Seaman, Craig
title: A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine
date: 2021-10-28
journal: Haemophilia
DOI: 10.1111/hae.14442
sha: 808ecc9d5f39fe7404453ebffbe6eed4d3a1d3cb
doc_id: 960335
cord_uid: pbeo2ffn

nan

In an effort to fight the ongoing SARS-CoV-2 pandemic, the mRNA-1273 SARS-CoV-2 vaccine manufactured by Moderna has been granted Emergency Use Authorization, because of its high efficacy and safety profile. 1 We report the first documented case of AHA after receiving the mRNA-1273 SARS-CoV-2 vaccine.

This is a 70-year-old male patient with a past medical history of 

AHA is a rare disorder caused by autoantibodies against endogenous 

Our patient, without a prior history of bleeding, presented with clinical and laboratory findings consistent with AHA 8 days after receiving the first dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first case report suggesting a possible etiologic contribution of mRNA 1273 SARS-CoV-2 vaccine to AHA. Continuing surveillance and timely reporting are needed to increase awareness about the possibility of this rare disease in those receiving the vaccine.

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors

Acquired factor VIII inhibitors

WFH guidelines for the management of hemophilia

Acquired hemophilia A: updated review of evidence and treatment guidance

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

A case of acquired haemophilia following H1N1 vaccination

Acquired factor VIII haemophilia following influenza vaccination

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine